Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Sarcoma 1 Pituitary Neoplasms 1 Pituitary ACTH Hypersecretion 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Liposarcoma 1 Leukoplakia, Oral 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Adenocarcinoma, Follicular 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 62 Ifosfamide 39 Gemcitabine 29 Radiotherapy 27 Filgrastim 27 Cyclophosphamide 26 Docetaxel 19 Vincristine 18 pembrolizumab 17 Etoposide 17 pazopanib 16 Cisplatin 16 Nivolumab 15 Trabectedin 14 apatinib 13 Magnetic Resonance Spectroscopy 13 Carboplatin 12 Irinotecan 11 Bevacizumab 11 anlotinib 10 Temozolomide 10 Surgical Procedures, Operative 10 Sirolimus 10 camrelizumab 9 Sorafenib 9 Paclitaxel 9 Ipilimumab 9 Injections 9 Dactinomycin 9 Topotecan 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Sarcoma × Rosiglitazone × Clear all

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡